This complex subclonal architecture is further supported by recent longitudinal studies, which showed the emergence of previously undetectable subclones in relapsed-refractory MM patients treated with IMIDs, BRAF inhibitors, or anti-BCMA CAR T cells5,6,25,26. This evidence concerns the gene BRAF and Miyoshi myopathy.